Method Of Detaching Cells, Digesting Tissue Or Establishing A Primary Culture Patents (Class 435/378)
-
Patent number: 11077230Abstract: The invention provides a method for decellularising a tissue the method comprising the steps of: a) adding a tissue to be decellularised to a decellularisation vessel; b) adding a decellularisation medium comprising at least one detergent and/or at least one enzyme to the vessel; c) introducing a supercritical fluid to the vessel; and d) maintaining contact of the tissue with the supercritical fluid for a time sufficient to substantially decellularise the tissue.Type: GrantFiled: October 18, 2016Date of Patent: August 3, 2021Assignee: VIDEREGEN LIMITEDInventor: Tahera Ansari
-
Patent number: 10912864Abstract: Compositions including a first soft tissue-derived matrix and a second soft tissue-derived matrix are provided, as well as methods of making such compositions. In some embodiments, the composition comprises delipidated, decellularized adipose tissue-derived matrix and delipidated, decellularized fascial tissue-derived matrix, which may be combined in various proportions. Such adipose-fascia matrix compositions provide improved volume retention when implanted into a patient. The composition may further include exogenous cells or other substances, and/or a carrier. The composition is suitable for use inplastic surgery procedures, including reconstructive or cosmetic surgery procedures, as well as procedures for wound treatment and tissue regeneration.Type: GrantFiled: May 31, 2019Date of Patent: February 9, 2021Assignee: Musculoskeletal Transplant FoundationInventors: Benjamin Schilling, Andrew Madans, Abigail Phipps, Thomas Tylutki, Todd Nilsen, Yen-Chen Huang, Evangelia Chnari
-
Patent number: 10883119Abstract: Nucleases and methods of using these nucleases for genetic alteration of red blood cells (RBCs), for example for providing for a protein lacking in a monogenic disorder or a biologic for the treatment of exposure to a toxin using genetically altered RBCs.Type: GrantFiled: July 11, 2013Date of Patent: January 5, 2021Assignee: Sangamo Therapeutics, Inc.Inventor: Gregory J. Cost
-
Patent number: 10874764Abstract: The present invention relates to a tissue-engineered intervertebral disc (IVD) suitable for total disc replacement in a mammal and methods of fabrication. The IVD comprises a nucleus pulposus structure comprising a first population of living cells that secrete a hydrophilic protein and an annulus fibrosis structure surrounding and in contact with the nucleus pulposus structure, the annulus fibrosis structure comprising a second population of living cells and type I collagen. The collagen fibrils in the annulus fibrosis structure are circumferentially aligned around the nucleus pulposus region due to cell-mediated contraction in the annulus fibrosis structure. Also disclosed are methods of fabricating tissue-engineered intervertebral discs.Type: GrantFiled: June 16, 2019Date of Patent: December 29, 2020Assignee: Cornell UniversityInventors: Lawrence J. Bonassar, Roger Hartl, Robert D. Bowles, Harry H. Gebhard
-
Patent number: 10724003Abstract: The present invention relates to a method of culturing primitive-like macrophages from stem cells, a kit when used in the method thereof and uses of the primitive like macrophage for in-vitro disease models and for screening compounds for therapy. One embodied culture method comprises contacting and incubating embryonic stem cells or induced pluripotent stem cells with a serum-free culture media comprising a GSK3 inhibitor to differentiate stem cells into cells of the mesoderm lineage, followed by incubation with a culture media comprising Dickkopf-related protein 1 (DKK1) to differentiate the mesoderm into cells of hematopoietic lineage, maturing hematopoietic cells and incubating these cells with a culture media comprising M-CSF to drive differentiation into primitive-like macrophages.Type: GrantFiled: January 18, 2016Date of Patent: July 28, 2020Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: Hwei-In Shawn Lim, Tara Huber, Florent Ginhoux
-
Patent number: 10723793Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 3 (TGF-?3) are provided, particularly recognizing human and mouse TGF-?3, particularly antibodies and fragments that do not recognize or bind TGF-?1 or TGF-?2. Particular antibodies are provided which specifically recognize and neutralize TGF-?3. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-?3, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-?3 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof.Type: GrantFiled: June 10, 2016Date of Patent: July 28, 2020Assignee: Ludwig Institute for Cancer Research, Ltd.Inventors: Jacques Van Snick, Catherine Uyttenhove
-
Patent number: 10537665Abstract: The present disclosure relates to tissue matrix products. The products can includes tissue matrices that have holes or perforations located at certain positions to improve certain in vivo functions without substantial loss of strength or other important properties.Type: GrantFiled: September 9, 2016Date of Patent: January 21, 2020Assignee: LifeCell CorporationInventor: Alexander Ringo
-
Patent number: 10453555Abstract: Regulated changes in gene expression underlie many biological processes, but globally profiling cell-to-cell variations in transcriptional regulation is problematic when measuring single cells. Transcriptome-wide identification of regulatory heterogeneities can be robustly achieved by randomly collecting small numbers of cells followed by statistical analysis. However, this stochastic-profiling approach blurs out the expression states of the individual cells in each pooled sample. Various aspects of the disclosure show that the underlying distribution of single-cell regulatory states can be deconvolved from stochastic-profiling data through maximum-likelihood inference. Guided by the mechanisms of transcriptional regulation, the disclosure provides mixture models for cell-to-cell regulatory heterogeneity which result in likelihood functions to infer model parameters.Type: GrantFiled: January 19, 2016Date of Patent: October 22, 2019Assignee: University of Virginia Patent FoundationInventors: Kevin Janes, Sameer Bajikar, Fabian Theis, Christiane Fuchs
-
Patent number: 10444126Abstract: Methods are provided for directly converting histopathologically processed biological samples, tissues, and cells into a multiuse biomolecule lysate. This method allows for simultaneous extraction, isolation, solubilization, and storage of all biomolecules contained within the histopathologically processed biological sample, thereby forming a representative library of said sample. This multi-use biomolecule lysate is dilutable, soluble, capable of being fractionated, and used in biochemical assays.Type: GrantFiled: September 29, 2015Date of Patent: October 15, 2019Assignee: EXPRESSION PATHOLOGY, INC.Inventors: Marlene M. Darfler, David B. Krizman
-
Patent number: 10428309Abstract: The present invention provides various improved systems and methods for obtaining, generating, culturing, and handling cells, such as stem cells (including induced pluripotent stem cells or iPSCs) and differentiated cells, as well as cells and cell panels produced using such systems and methods, and uses of such cells and cell panels.Type: GrantFiled: June 27, 2014Date of Patent: October 1, 2019Assignee: New York Stem Cell Foundation, Inc.Inventors: Scott Noggle, Kevin Eggan, Stephen Chang, Susan Solomon
-
Patent number: 10294450Abstract: A fluid pumping and bioreactor system including at least two cassettes, at least one storage reservoir, at least one bioreactor, at least one manifold including valve modules, and tubing to connect the cassettes to the storage reservoir and the bioreactor. The cassettes can include pumps, valves, and fluid conduits and can be communicatively connected to the at least one manifold. The bioreactor can include an adapter and fluid conduits extending through the adapter from the exterior of the bioreactor to the interior of the bioreactor. System and method for generating a tissue for transplant by decellularizing and recellularizing a supplied tissue.Type: GrantFiled: October 7, 2016Date of Patent: May 21, 2019Assignee: DEKA Products Limited PartnershipInventors: Dean Kamen, Jason A. Demers, Frederick Morgan, Timothy D. Moreau, Brian D. Tracey, Matthew Ware, Dirk A. van der Merwe, Richard J. Lanigan, Michael A. Baker, David Blumberg, Jr.
-
Patent number: 10016528Abstract: Products, processes, compositions, kits, and methods are provided for cartilage-derived implants. The implants can exhibit resistance to enzyme (e.g., collagenase, protease, etc.) digestion compared to the source tissue from which they were derived while still having one or more mechanical properties comparable to the source tissue from which they were derived. The implants can also have a plurality of molecular bridges between molecules of the cartilaginous material. The molecular bridges can connect one or more collagen fibrils and/or/with one or more glycosaminoglycans. The implants can also be treated with cationic detergent, packaged and sterilized with or without additional components, and surgically implanted into subjects.Type: GrantFiled: September 4, 2014Date of Patent: July 10, 2018Inventor: Eran Rosines
-
Patent number: 9951312Abstract: Chondrocytes are prepared from perichondrocytes. The present invention provides a cell derived from a perichondrial tissue, the cell being capable of differentiating into a chondrocyte. The present invention also provides a method of preparing the above-described cell and a composition comprising the same. A method of preparing a chondrocyte and a medium for use in the method are also provided.Type: GrantFiled: January 23, 2008Date of Patent: April 24, 2018Assignee: Yokohama City UniversityInventors: Hideki Taniguchi, Shinji Kobayashi
-
Patent number: 9890352Abstract: An injectable tissue engineered cartilage in vitro construction apparatus, comprising an incubator (1), a centrifugal device arranged in the incubator (1), and a control system for controlling a temperature in the incubator (1) and an action of the centrifugal device. The centrifugal device comprises a centrifuge, a container base (2) mounted onto the centrifuge, a dosing system for adding preparation reagent, and a stirring system for stirring the reagent. With a controller (17) and a pH sensor (16), a measured pH value will be transmitted by the pH sensor (16) to the controller (17) in real time. The controller (17) controls an action of a driving mechanism via a control module II (21), to drive a piston rod to add NaOH solution into a container tank (6). When the pH value of the solution falls in a predetermined range, the driving mechanism is stopped, to precisely control the pH value of the solution.Type: GrantFiled: July 21, 2014Date of Patent: February 13, 2018Assignee: FIRST AFFILIATED HOSPITAL, THIRD MILITARY MEDICAL UNIVERSITY, CHINESE PEOPLE'S LIBERATION ARMY, P.R. CHINAInventors: Fuyou Wang, Junli Liu, Liu Yang, Ying Zhang, Guangxing Chen, Lin Guo, Xiaojun Duan
-
Patent number: 9574174Abstract: A method for determining the effect of a plurality of culture conditions on a cell, comprising the steps of: a) providing a first set of groups of cell units each comprising one or more cells, and exposing said groups to desired culture conditions; (b) pooling two or more of said groups to form at least one second pool; (c) subdividing the second pool to create a further set of groups of cell units; (d) exposing said further groups to desired culture conditions; (e) optionally, repeating steps (b)-(d) iteratively as required; and (f) optionally assessing the effect on a given cell unit of the culture conditions to which it has been exposed.Type: GrantFiled: April 5, 2013Date of Patent: February 21, 2017Assignee: PLASTICELL LIMITEDInventor: Yen Choo
-
Patent number: 9567564Abstract: Human progenitor cells are extracted from perivascular tissue of human umbilical cord. The progenitor cell population proliferates rapidly, and harbors osteogenic progenitor cells and MHC?/? progenitor cells, and is useful to grow and repair human tissues including bone.Type: GrantFiled: May 28, 2013Date of Patent: February 14, 2017Assignee: Tissue Regeneration Therapeutics Inc.Inventors: John E. Davies, Dolores Baksh, Rahul Sarugaser, Morris Hosseini, Antony D. S. Lickorish
-
Patent number: 9550975Abstract: Objects of the present invention are to provide a method for directly obtaining pluripotent stem cells from body tissue and the thus obtained pluripotent stem cells. The present invention relates to SSEA-3 (+) pluripotent stem cells that can be isolated from body tissue.Type: GrantFiled: July 14, 2010Date of Patent: January 24, 2017Inventors: Mari Dezawa, Yoshinori Fujiyoshi, Youichi Nabeshima, Shohei Wakao
-
Patent number: 9447379Abstract: Methods and compositions for differentiating tissue resident multipotent mesenchmal stromal cells (MSCs) such as adipose tissue resident MSCs into a hematopoietic lineage are described.Type: GrantFiled: February 28, 2011Date of Patent: September 20, 2016Inventors: Reza Izadpanah, Eckhard Alt
-
Patent number: 9181529Abstract: Methods and composition for differentiation of pluripotent stem cells are provided. For example, in certain aspects methods including screening of optimal differentiation conditions for a selected stem cell clone in a selected batch of culture medium and use of the determined optimal condition for differentiation into a specific cell lineage.Type: GrantFiled: October 19, 2011Date of Patent: November 10, 2015Assignee: Cellular Dynamics International, Inc.Inventors: Steven Kattman, Wen Bo Wang, Peter Fuhrken, Nathan Meyer, Matthew George, Casey Stankewicz
-
Patent number: 9139815Abstract: The invention relates to stems cells derived from bone marrow, and uses thereof in tissue regeneration.Type: GrantFiled: May 1, 2007Date of Patent: September 22, 2015Assignee: Pharma Pass II LLCInventors: Cornelis H. Kleinbloesem, Paul Giles
-
Patent number: 9068169Abstract: The invention relates to the discovery of a selective cell surface marker that permits the selection of a unique subset of pancreatic stems cells having a high propensity to differentiate into insulin producing cells or into insulin producing cell aggregates.Type: GrantFiled: May 2, 2008Date of Patent: June 30, 2015Assignee: RENEURON, INC.Inventors: Wen-Ghih Tsang, Tianli Zheng, Wei Liu
-
Publication number: 20150147409Abstract: A combination of therapeutic factors derived from non-adherent or poorly adherent stromal vascular fraction (SVF) cells exposed to protein-free basal medium are disclosed.Type: ApplicationFiled: November 21, 2014Publication date: May 28, 2015Inventors: Keith L. March, Brian H. Johnstone
-
Patent number: 9040272Abstract: The present invention provides a method and system for using eye-safe infrared energy from a Class I laser to manipulate cells in culture. The laser energy produces one or more phase boundary propulsion events, which generate hydrodynamic forces sufficient to manipulate cells at the focal point.Type: GrantFiled: June 13, 2011Date of Patent: May 26, 2015Assignee: Hamilton Thorne, Inc.Inventors: Diarmaid H. Douglas-Hamilton, Thomas G. Kenny
-
Publication number: 20150132266Abstract: A method of isolating non-expanded post-natal multilineage-inducible cells has the steps of obtaining a biological sample from an animal; isolating bone marrow from the biological sample, isolating total nuclear cells (TNCs) obtained from the bone marrow, incubating the total nuclear cells in the presence of an antibody or a cell adhesion substrate, separating the cells to isolate non-expanded post-natal multilineage-inducible cells and isolating the non-expanded post-natal multilineage-inducible cells in the absence of expansion.Type: ApplicationFiled: November 13, 2014Publication date: May 14, 2015Applicants: THE UNIVERSITY OF MIAMI, GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENTInventors: Paul C. Schiller, Gianluca D'Ippolito
-
Patent number: 9029145Abstract: The present invention provides an isolated population of chondrocyte precursor cells wherein 1% or less of the cells express Oct4, Nanog and/or TRA-1-60, 7% or less of the cells express no collagen II, collagen X, CD105 or Stro-1 and 85% or more of the cells express CBFA1, methods for preparing such cells and uses of chondrocyte cells derived from said precursor cells.Type: GrantFiled: April 8, 2011Date of Patent: May 12, 2015Assignee: The University Court of the University of EdinburghInventors: Brendon Stewart Noble, David Matthew Pier
-
Patent number: 9028840Abstract: The present invention discloses an ex vivo method for producing a preparation containing CD4+ T cells specific for EBV structural antigens for use in the prophylaxis and treatment of patients with a reduced T cell activity in order to prevent or treat growth of EBV infected B cells.Type: GrantFiled: November 27, 2008Date of Patent: May 12, 2015Assignees: Helmholtz Zentrum Munchen Deutsches Forschungzentrum fur Gesundheit und Umwelt (GmbH), Deutsches Krebsforschungzentrum (DKFZ)Inventors: Dinesh Adhikary, Uta Behrends, Josef Mautner, Henri-Jacques Delecluse, Regina Feederle
-
Patent number: 9023642Abstract: A bioreactor and method that permits continuous and simultaneous short, moderate, or long term cell culturing of one or more cell types or tissue in a laminar flow configuration is disclosed, where the bioreactor supports at least two laminar flow zones, which are isolated by laminar flow without the need for physical barriers between the zones. The bioreactors of this invention are ideally suited for studying short, moderate and long term studies of cell cultures and the response of cell cultures to one or more stressors such as pharmaceuticals, hypoxia, pathogens, or any other stressor. The bioreactors of this invention are also ideally suited for short, moderate or long term cell culturing with periodic cell harvesting and/or medium processing for secreted cellular components.Type: GrantFiled: July 6, 2007Date of Patent: May 5, 2015Assignee: The University of Houston SystemInventors: Stanley J. Kleis, Sandra K. Geffert, Steve R. Gonda
-
Patent number: 9023273Abstract: Methods for processing tissue are provided. In some embodiments, the methods comprise methods for decellularizing tissue samples by applying high hydrostatic pressure to the tissues samples. In some embodiments, the methods comprise methods for thawing tissue samples and/or reducing the bioburden in a sample by applying high hydrostatic pressure to the tissue samples.Type: GrantFiled: August 17, 2010Date of Patent: May 5, 2015Assignee: LifeCell CorporationInventor: Benjamin Kibalo
-
Patent number: 9023614Abstract: A method for rapidly collecting cells from a surface, such as a surface bearing fingerprints, for subsequent macromolecular analysis involves dispensing a predetermined amount of an aqueous solution onto the surface, and subjecting the aqueous solution to ultrasound waves to promote a detachment of the cells from the surface. Extraction of macromolecules such as DNA from the cells can be effected directly in the solution containing the collected cells by further subjecting the solution to ultrasound waves for a prescribed period of time to lyse the cells, and then extracting the DNA.Type: GrantFiled: July 9, 2004Date of Patent: May 5, 2015Inventor: Tofy Mussivand
-
Publication number: 20150119970Abstract: The present invention provides a valved stent that can provide a valve function without blocking a branch blood vessel, and also can provide a valve function with minimum covering of blood vessel tissue in a stent indwelling section. Specifically, a cylindrical stent body 4 is provided. A leaflet 5 that can open/close a blood vessel 2 in a blood flow direction is provided. The leaflet 5 is composed of connective tissue and protrudes radially inward from the stent body 4. An inside and an outside of the stent body 4 radially communicate with each other. The stent does not block a branch blood vessel 8. An area of the blood vessel covered with the stent is reduced.Type: ApplicationFiled: January 7, 2015Publication date: April 30, 2015Inventors: Yasuhide NAKAYAMA, Tomonori OIE
-
Publication number: 20150118751Abstract: A matrix, including epithelial basement membrane, for inducing repair of mammalian tissue defects and in vitro cell propagation derived from epithelial tissues of a warm-blooded vertebrate.Type: ApplicationFiled: October 7, 2014Publication date: April 30, 2015Inventor: Alan R. Spievack
-
Publication number: 20150110747Abstract: Bone grafts and constructs including stem cells are provided. Example bone grafts include osteogenic stem cells seeded on a scaffold of osteoconductive cortico-cancellous chips and/or osteoinductive demineralized bone. Example constructs include extracellular matrix on a synthetic scaffold, in which the ECM is secreted from MSCs seeded onto the synthetic scaffold. Also provided are methods of making the present bone grafts and scaffolds. Further provided are methods of promoting bone healing and treating wound healing, by administering the present bone grafts and constructs to a mammal in need thereof. Also provided are kits that include the present bone grafts and/or constructs, or components thereof.Type: ApplicationFiled: October 18, 2013Publication date: April 23, 2015Inventors: Archana Bhat, Shairali Rao, Daniel Laskowitz
-
Publication number: 20150110756Abstract: The present invention provides a prosthetic tissue or sheet capable of withstanding implantation operations, which can be used in actual operation and can be produced by culture. The present invention also provides a novel therapy which can substitute for cell therapy. Particularly, the present invention provides a method for producing a prosthetic tissue comprising a cell derived from a part other than myocardium and capable of withstanding implantation operation. The above-described objects of the present invention were partially achieved by finding that by culturing cells under specific culture conditions, the cells are unexpectedly organized into a tissue, and the resultant prosthetic tissue is capable of being detached from culture dishes. The present invention also provides a three-dimensional structure applicable to heart, comprising a cell derived from a part other than the myocardium of an adult.Type: ApplicationFiled: October 27, 2014Publication date: April 23, 2015Inventors: Hikaru MATSUDA, Yoshiki Sawa, Satoshi Taketani, Shigeru Miyagawa
-
Publication number: 20150110753Abstract: The present invention provides biomatrix scaffolds, a tissue extract enriched for extracellular matrix components and bound growth factors, cytokines and hormones, and methods of making and using same.Type: ApplicationFiled: August 8, 2014Publication date: April 23, 2015Applicant: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILLInventors: Yunfang WANG, Lola Cynthia McAdams REID, Mitsuo YAMAUCHI, Cai-Bin CUI, Andrew Zhuang WANG, Michael Edward WERNER
-
Patent number: 9012222Abstract: Noncultured Wharton's Jelly stem cells and methods of their purification, storage and use are provided.Type: GrantFiled: January 29, 2013Date of Patent: April 21, 2015Assignee: Auxocell Laboratories, Inc.Inventor: Rouzbeh R. Taghizadeh
-
Patent number: 8993323Abstract: The present invention is directed to a method of deriving pluripotent embryonic stem cells from mouse blastocysts or from primordial germ cells from a post-implantation mouse embryo, or of maintaining or growing pluripotent embryonic stem cells from a mouse, or of expanding human hematopoietic stem cells or human hematopoietic precursor cells. The methods include the step of cultivating the stem cells or precursor cells for at least one passage in a culture medium preconditioned by the rabbit fibroblast cell line Rab9 (ATCC catalogue CRL1414) and containing less than 0.1 ng/ml Leukemia Inhibitory Factor (LIF).Type: GrantFiled: September 19, 2013Date of Patent: March 31, 2015Assignee: ThromboGenics N.V.Inventor: Luc Schoonjans
-
Patent number: 8993322Abstract: Methods and kits of releasing cells are provided. The method comprises the steps of providing cultured cells on a cell culture support comprising a multi layer polyelectrolyte coating immobilized on a substrate, and releasing the cultured cells from the cell culture support by a releasing solution comprising DMSO. The kit comprises a cell culture support and a releasing solution. The releasing solution comprises DMSO.Type: GrantFiled: February 25, 2013Date of Patent: March 31, 2015Assignee: General Electric CompanyInventors: Slawomir Rubinsztajn, Prameela Susarla, Reginald Donovan Smith, Evelina Roxana Loghin
-
Patent number: 8986678Abstract: The present invention relates to methods of in vitro preparation of a parental cell bank (PCB) from foetal tissue consisting of foetal epiphyseal tissue, foetal Achilles tendon tissue and foetal skin tissue, using a rapid mechanical primary cell culture selection of cell type to be used in methods for wound and tissue repair.Type: GrantFiled: July 10, 2012Date of Patent: March 24, 2015Assignee: Centre Hospitalier Universitaire VaudoisInventor: Lee Ann Laurent-Applegate
-
Publication number: 20150079626Abstract: The present invention relates to a method of obtaining a cell population containing cancer stem cells, which comprises culturing iPS cells in the presence of culture supernatant of cancer cells.Type: ApplicationFiled: March 18, 2014Publication date: March 19, 2015Applicants: LSIP, LLC, National University Corporation Okayama UniversityInventors: Masaharu SENO, Akifumi MIZUTANI, Tomonari KASAI
-
Patent number: 8980630Abstract: The present invention relates to stem cells obtained from the amnion and their methods of obtaining and culturing. The present invention further relates to compositions comprising amnion-derived stems cells (ADSCs) and to methods of using ADSCs.Type: GrantFiled: June 28, 2007Date of Patent: March 17, 2015Assignee: Rutgers, The State University of New JerseyInventors: Dale Woodbury, Akiva J. Marcus
-
Patent number: 8945920Abstract: The invention concerns a method for culturing cells derived from the adipose tissue and in particular the stromal vascular fraction (SVF) to induce formation of cardiomyocytes, the use of the cells obtained by said culture method to reconstitute an ischemized cardiac zone, in particular following an infarction, as well as a pharmaceutical composition containing said cells. The method for obtaining cardiac cells comprises at least the following steps: a) selecting cardiomyogenic cells from the stromal vascular fraction (SVF); b) culturing the cells selected at step a) in a liquid medium optimized for expanding ex vivo the cardiomyogenic cells; c) maintaining and expanding said cells by successive passes in the liquid medium; and d) obtaining cardiac cells.Type: GrantFiled: January 26, 2007Date of Patent: February 3, 2015Assignee: Centre National de la Recherche ScientifiqueInventors: Louis Casteilla, Valérie Planat-Benard, Luc Penicaud, Carine Chanut
-
Publication number: 20150024490Abstract: Methods of cell culture using patterned SAM arrays are disclosed. Advantageously, the disclosed methods use SAM arrays presenting adhesion peptides to grow confluent monolayers that can invaginate to form an embryoid body.Type: ApplicationFiled: September 15, 2014Publication date: January 22, 2015Inventors: Angela W. Xie, William L. Murphy
-
Publication number: 20150018966Abstract: The invention provides an improved method of producing a natural, acellular matrix scaffold for subsequent use in tissue-engineered replacement of tissues such as the bladder. Decellularisation is carried out on an expanded or distended bladder and the product retains the strength and compliance of natural material. The invention also provides use of the matrix scaffolds as wound healing material and to investigate tissue structure and function in vitro.Type: ApplicationFiled: July 29, 2014Publication date: January 15, 2015Inventors: Fiona Bolland, Jennifer Southgate, Sotirios Korossis, Eileen Ingham
-
Patent number: 8932858Abstract: Hydrophobically modified polysaccharide compositions, articles incorporating the compositions, and methods for cell culture, automatic release of cells, and release of cell culture coating from a substrate or the cell culture articles incorporating the coating compositions, as defined herein.Type: GrantFiled: March 4, 2009Date of Patent: January 13, 2015Assignee: Corning IncorporatedInventors: Wendy A. Baker, Dana C. Bookbinder, Theresa Chang, Robert R. Hancock, Jr.
-
Publication number: 20150011543Abstract: Pyrimido[4,5-b]indole derivatives are provided. These compounds are useful to expand hematopoietic stem cell populations, particularly, human hematopoietic stem cell populations. The compounds are also useful in the medical treatment of diseases that involve hematopoietic stem cells.Type: ApplicationFiled: January 25, 2013Publication date: January 8, 2015Applicant: UNIVERSITE DE MONTREALInventors: Guy Sauvageau, Yves Gareau
-
Patent number: 8927282Abstract: The present invention relates to cell and tissue culture. In particular, the present invention provides a method for preparing an organotypic culture using dissociated cells or microexplants obtained from an animal organ. The method for preparing an organotypic culture comprises culturing cells from an organ on a surface characterized in that the cells are compacted. The invention further relates to a high-throughput method for the preparation of a collection of organotypic cultures. The invention further relates to a device for carrying out a method of organotypic culture according to the invention.Type: GrantFiled: June 15, 2006Date of Patent: January 6, 2015Assignee: Capsant Neurotechnologies S.A.Inventor: Luc Stoppini
-
Publication number: 20150004702Abstract: The present disclosure provides an automated system for isolating stromal vascular fraction cells from the mammalian tissue. The system comprises a plurality of containers for storing buffer solutions, tissue samples and digestive buffers. A tissue processing unit fluidly connected to the containers for processing the tissues. The tissue processing unit performs at least one of washing process, digestion process, phase separation process and combination thereof for separating an aqueous fraction of tissue and a fatty fraction. A cell concentration unit fluidly connected to the tissue processing unit for receiving the aqueous fraction of tissue from the tissue processing unit. The cell concentration unit filters the aqueous fraction of tissue by vibrating a filtration assembly by a filter vibrator. A waste collection unit fluidly connectable to the tissue processing unit and cell concentration unit is provided for receiving waste tissues.Type: ApplicationFiled: August 28, 2012Publication date: January 1, 2015Applicant: STEMPEUTICS RESEARCH PRIVATE LIMITEDInventors: Swathi Sundar Raj, Venkatesh Gopal, Nancy Priya, Balagangadhara Krishnegowda, Prajod Thiruvampattil, Anish Sen Majumdar, Murali Cherat
-
Publication number: 20140363891Abstract: A portable apparatus for collection and processing of human biological material, such as containing adipose extracted during a lipoplasty procedure, is useful for multi-step processing to prepare a concentrated product (e.g., stromal vascular fraction) or a fat graft composition. The apparatus has a container with a containment volume with a tissue retention volume and a filtrate volume separated by a filter and with a tapered portion to a collection volume for collecting concentrate product. Inlet and suction ports provide access to the tissue retention volume and filtrate volume, respectively, and an extraction port provides versatile access for removal of target processed concentrate material or fat graft material, which access may be via a lumen through a rotatable mixer shaft. Access ports may be configured for access only from above the container. A method of processing adipose tissue to concentrate leuko stromal vascular cells includes multi-step processing using a portable container.Type: ApplicationFiled: January 11, 2013Publication date: December 11, 2014Applicant: THE GID GROUP, INC.Inventors: Ramon Llull, Adam J. Katz, William W. Cimino
-
Publication number: 20140342369Abstract: The present invention relates to the generation of stable haploid cell cultures, uses of said cells in forward and reverse genetics, especially the identification of target genes associated with a modified phenotype and in particular identifying genetic targets associated with toxin resistance, especially ricin toxicity resistance, and therapeutic uses of target compounds.Type: ApplicationFiled: November 30, 2012Publication date: November 20, 2014Applicant: IMBA - INSTITUT FÜR MOLEKULARE BIOTECHNOLOGIE GMBHInventors: Ulrich Elling, Josef Penninger, Jasmin Taubenschmid
-
Publication number: 20140335057Abstract: The present invention relates to novel methods of growing at least 100 million minimally-passaged fibroblasts from a small biopsy specimen. The invention includes methods wherein a small biopsy specimen is needed directly into a large tissue culture flask, and passaged so more than three times.Type: ApplicationFiled: May 19, 2014Publication date: November 13, 2014Applicant: FIBROCELL TECHNOLOGIES, INC.Inventors: John Maslowski, Myrna F. Thomas, Marie A. Lindner